Arrowstreet Capital’s ResMed RMD Stock Holding History

Arrowstreet Capital’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$101M	Buy	450,250 +176,641	+65%	+$44M	0.05%	305
2025 Q4	$65.9M	Buy	273,609 +173,606	+174%	+$44.4M	0.04%	395
2025 Q3	$27.4M	Buy	100,003 +98,496	+6,536%	+$26.9M	0.02%	635
2025 Q2	$389K	Buy	+1,507	New	+$359K	﹤0.01%	1793
2025 Q1	–	Sell	-216,127	Closed	-$49.4M	–	1985
2024 Q4	$49.4M	Buy	216,127 +17,951	+9%	+$4.32M	0.04%	376
2024 Q3	$48.4M	Buy	198,176 +176,033	+795%	+$39.3M	0.04%	342
2024 Q2	$4.24M	Buy	+22,143	New	+$4.49M	﹤0.01%	887
2023 Q4	–	Sell	-10,339	Closed	-$1.53M	–	1538
2023 Q3	$1.53M	Sell	10,339 -106,000	-91%	-$19.2M	﹤0.01%	904
2023 Q2	$25.4M	Sell	116,339 -16,712	-13%	-$3.72M	0.03%	353
2023 Q1	$29.1M	Sell	133,051 -58,893	-31%	-$12.8M	0.04%	346
2022 Q4	$39.9M	Buy	191,944 +15,817	+9%	+$3.48M	0.06%	272
2022 Q3	$38.4M	Buy	176,127 +150,642	+591%	+$34.3M	0.06%	265
2022 Q2	$5.34M	Sell	25,485 -14,646	-36%	-$3.12M	0.01%	595
2022 Q1	$9.73M	Sell	40,131 -192,134	-83%	-$46.5M	0.01%	516
2021 Q4	$60.5M	Buy	232,265 +41,998	+22%	+$10.9M	0.07%	258
2021 Q3	$50.1M	Buy	190,267 +171,267	+901%	+$46.8M	0.06%	318
2021 Q2	$4.68M	Sell	19,000 -84,496	-82%	-$17.8M	0.01%	1094
2021 Q1	$20.1M	Sell	103,496 -130,332	-56%	-$26.1M	0.03%	589
2020 Q4	$49.7M	Buy	233,828 +29,863	+15%	+$5.95M	0.07%	282
2020 Q3	$35M	Buy	203,965 +141,315	+226%	+$26.1M	0.06%	348
2020 Q2	$12M	Buy	62,650 +52,450	+514%	+$8.58M	0.02%	699
2020 Q1	$1.5M	Buy	10,200 +6,300	+162%	+$1M	﹤0.01%	1166
2019 Q4	$604K	Buy	+3,900	New	+$562K	﹤0.01%	1459
2019 Q2	–	Sell	-5,700	Closed	-$593K	–	1655
2019 Q1	$593K	Sell	5,700 -330,798	-98%	-$34.1M	﹤0.01%	1445
2018 Q4	$38.3M	Sell	336,498 -638,645	-65%	-$68.4M	0.1%	211
2018 Q3	$112M	Buy	975,143 +894,615	+1,111%	+$98M	0.25%	95
2018 Q2	$8.34M	Buy	+80,528	New	+$8.15M	0.02%	447
2016 Q4	–	Sell	-95,200	Closed	-$6.17M	–	2370
2016 Q3	$6.17M	Buy	95,200 +38,900	+69%	+$2.59M	0.02%	593
2016 Q2	$3.56M	Buy	56,300 +5,400	+11%	+$318K	0.01%	674
2016 Q1	$2.94M	Buy	50,900 +44,400	+683%	+$2.51M	0.01%	687
2015 Q4	$349K	Sell	6,500 -98,100	-94%	-$5.53M	﹤0.01%	1217
2015 Q3	$5.33M	Buy	104,600 +58,900	+129%	+$3.17M	0.03%	515
2015 Q2	$2.58M	Buy	+45,700	New	+$2.88M	0.01%	586
2015 Q1	–	Sell	-62,467	Closed	-$3.5M	–	1187
2014 Q4	$3.5M	Buy	+62,467	New	+$3.26M	0.02%	557
2014 Q3	–	Sell	-5,835	Closed	-$295K	–	1101
2014 Q2	$295K	Sell	5,835 -19,154	-77%	-$949K	﹤0.01%	877
2014 Q1	$1.12M	Sell	24,989 -841,540	-97%	-$37.8M	0.01%	799
2013 Q4	$40.8M	Sell	866,529 -215,680	-20%	-$10.9M	0.22%	109
2013 Q3	$57.2M	Buy	1,082,209 +378,639	+54%	+$18.4M	0.36%	70
2013 Q2	$31.8M	Buy	+703,570	New	+$33.4M	0.24%	103

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arrowstreet Capital's RMD Position: Q1 2026 in Review

Arrowstreet Capital increased its ResMed (RMD) stake by 65% in Q1 2026, buying an estimated $44M and bringing the position to 450,250 shares worth $101M. The position accounts for 0.05% of the portfolio, ranked #305.

Arrowstreet Capital first reported a position in RMD in Q2 2013 and has held it in 39 quarters since. The position peaked at $112M in Q3 2018. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Arrowstreet Capital held 450,250 shares of ResMed worth $101M as of Q1 2026.
Arrowstreet Capital bought 176,641 ResMed shares in Q1 2026, an estimated $44M.
ResMed made up 0.05% of Arrowstreet Capital's portfolio in Q1 2026, its #305 holding.
Arrowstreet Capital first reported a position in ResMed in Q2 2013 and has held it in 39 quarters since.
Arrowstreet Capital's ResMed position peaked at $112M in Q3 2018.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.